Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 11/20 | 0.45 |
| ▸ | DRD2 | P14416 | 9/20 | 0.45 |
| ▸ | DRD3 | P35462 | 9/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.42 |
| ▸ | SCD | O00767 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL123255 | 0.99 | DRD4 (0.44) | DRD4DRD2DRD3PDE10ASCD | |
| SCHEMBL12742560 | 0.89 | DRD4 (0.56) | DRD4DRD2DRD3PDE10AHTR2C | |
| Hydrochloric Acid SCHEMBL125370 | 0.88 | DRD4 (0.55) | DRD4DRD2DRD3PDE10AHTR2C | |
| SCHEMBL172328 | 0.85 | DRD4 (0.50) | DRD4DRD2DRD3PDE10AHTR2C | |
| SCHEMBL128142 | 0.84 | DRD4 (0.49) | DRD4DRD2DRD3HTR2CHTR1A | |
| Hydrochloric Acid SCHEMBL123987 | 0.84 | DRD4 (0.49) | DRD4DRD2DRD3PDE10AHTR2C | |
| SCHEMBL12742597 | 0.78 | PDE10A (0.43) | DRD4DRD2DRD3PDE10A | |
| Hydrochloric Acid SCHEMBL121579 | 0.77 | PDE10A (0.42) | DRD4DRD2DRD3PDE10A | |
| SCHEMBL172308 | 0.75 | KMT2A (0.42) | DRD4DRD2DRD3PDE10A | |
| SCHEMBL12742604 | 0.75 | PDE10A (0.39) | DRD4DRD2DRD3PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2201002-B1 | 5-HT7 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-03-07 | — | — | EP | disclosed |
| US-7910588-B2 | 5-HT7 receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910588-B2 | 5-HT7 receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-20100197700-A1 | 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-08-05 | — | — | US | disclosed |
| US-20100197700-A1 | 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-08-05 | — | — | US | disclosed |
| WO-2009048765-A1 | 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197700-A1 | 5-HT7 RECEPTOR ANTAGONISTS | HTR7, HTR1A, HTR2C | DRD4 349/4885DRD2 226/4885DRD3 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.